Literature DB >> 23861019

Is There a Role for Menopausal Hormone Therapy (MHT) for Cardiovascular Disease Prevention in Select Postmenopausal Women?

Alexis Cutchins1, Nanette K Wenger.   

Abstract

OPINION STATEMENT: Although the US Preventive Services Task Force and other contemporary guidelines recommend that Menopausal Hormone Therapy (MHT) not be used for prevention of chronic conditions, its use for prevention of cardiovascular disease remains controversial. The Women's Health Initiative and the Heart and Estrogen/progestin Replacement Study explored the benefits and risks of MHT for cardiovascular disease, primary and secondary prevention respectively, but challenges to these data include suboptimal hormone therapy adherence and the advanced age of the women at initiation of MHT. Here we discuss the recent literature impacting MHT management of the peri- and post-menopausal women who are concerned about cardiovascular disease risk.

Entities:  

Year:  2013        PMID： 23861019     DOI： 10.1007/s11936-013-0256-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN： 1092-8464


  23 in total

1.  2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L David Hillis; Peter K Smith; Jeffrey L Anderson; John A Bittl; Charles R Bridges; John G Byrne; Joaquin E Cigarroa; Verdi J Disesa; Loren F Hiratzka; Adolph M Hutter; Michael E Jessen; Ellen C Keeley; Stephen J Lahey; Richard A Lange; Martin J London; Michael J Mack; Manesh R Patel; John D Puskas; Joseph F Sabik; Ola Selnes; David M Shahian; Jeffrey C Trost; Michael D Winniford
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

2.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

3.  Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort.

Authors:  B de Lauzon-Guillain; A Fournier; A Fabre; N Simon; S Mesrine; M-C Boutron-Ruault; B Balkau; F Clavel-Chapelon
Journal:  Diabetologia       Date:  2009-07-23       Impact factor: 10.122

4.  Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.

Authors:  Christel Renoux; Sophie Dell'aniello; Edeltraut Garbe; Samy Suissa
Journal:  BMJ       Date:  2010-06-03

5.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Authors:  Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

6.  Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial.

Authors:  Andrea H Tackett; Alison L Bailey; Joanne Micale Foody; Julie M Miller; Carolyn Apperson-Hansen; E Magnus Ohman; Judith S Hochman; Sharon L Karnash; Robert M Califf; Eric J Topol; David J Moliterno
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

7.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.

Authors:  Lori Mosca; Emelia J Benjamin; Kathy Berra; Judy L Bezanson; Rowena J Dolor; Donald M Lloyd-Jones; L Kristin Newby; Ileana L Piña; Véronique L Roger; Leslee J Shaw; Dong Zhao; Theresa M Beckie; Cheryl Bushnell; Jeanine D'Armiento; Penny M Kris-Etherton; Jing Fang; Theodore G Ganiats; Antoinette S Gomes; Clarisa R Gracia; Constance K Haan; Elizabeth A Jackson; Debra R Judelson; Ellie Kelepouris; Carl J Lavie; Anne Moore; Nancy A Nussmeier; Elizabeth Ofili; Suzanne Oparil; Pamela Ouyang; Vivian W Pinn; Katherine Sherif; Sidney C Smith; George Sopko; Nisha Chandra-Strobos; Elaine M Urbina; Viola Vaccarino; Nanette K Wenger
Journal:  Circulation       Date:  2011-02-14       Impact factor: 29.690

8.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

9.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

Authors:  Deborah Grady; David Herrington; Vera Bittner; Roger Blumenthal; Michael Davidson; Mark Hlatky; Judith Hsia; Stephen Hulley; Alan Herd; Steven Khan; L Kristin Newby; David Waters; Eric Vittinghoff; Nanette Wenger
Journal:  JAMA       Date:  2002-07-03       Impact factor: 56.272

10.  Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.

Authors:  Madge R Vickers; Alastair H MacLennan; Beverley Lawton; Deborah Ford; Jeannett Martin; Sarah K Meredith; Bianca L DeStavola; Sally Rose; Anthony Dowell; Helen C Wilkes; Janet H Darbyshire; Tom W Meade
Journal:  BMJ       Date:  2007-07-11
View more
  1 in total

1.  Estrogen stimulates SREBP2 expression in hepatic cell lines via an estrogen response element in the SREBP2 promoter.

Authors:  Ye Meng; Lu Zong
Journal:  Cell Mol Biol Lett       Date:  2019-12-03       Impact factor: 5.787
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.